Edward D. Esplin: Clinician Responses to Germline Genetic Testing in Prostate Cancer Management
Edward D. Esplin, Clinical Geneticist at Invitae, shared on X:
“Up to 17% of prostate cancer patients have PGVs with germline testing
36% of universally tested PC patients had positive health outcomes 2/2 genetic testing results
Shore et al.
‘This study supports universal germline genetic testing for patients with prostate cancer, and it demonstrates the clinical utility of germline genetic testing results—both positive and negative—for…the care of patients and their families.’”
Authors: Neal Shore, Christopher Pieczonka, Sean Heron, Mukaram Gazi, David Cahn, Laurence H. Belkoff, Aaron Berger, Brian Mazzarella, Joseph Veys, Charles Idom, David Morris, Gautam Jayram, Alexander Engelman, Paul Dato, Richard Bevan-Thomas, David R. Wise, Mary Kay Hardwick, Susan Rojahn, Paige Layman, Brandie Heald, Rachel E. Ellsworth, Kathryn E. Hatchell, Robert L. Nussbaum, Sarah M. Nielsen, Edward D. Esplin
Source: Edward D. Esplin/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023